$-0.01 EPS Expected for BiondVax Pharmaceuticals Ltd. (BVXV)

August 18, 2018 - By Jason Dias

BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) Logo

Analysts expect BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) to report $-0.01 EPS on August, 30.They anticipate $0.73 EPS change or 98.65 % from last quarter’s $-0.74 EPS. After having $-0.62 EPS previously, BiondVax Pharmaceuticals Ltd.’s analysts see -98.39 % EPS growth. The stock increased 1.97% or $0.11 during the last trading session, reaching $5.69. About 5,352 shares traded. BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has declined 13.97% since August 18, 2017 and is downtrending. It has underperformed by 26.54% the S&P500.

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. The company has market cap of $37.19 million. The Company’s product candidate includes M-001, a synthetic peptide protein, which is in Phase II clinical development stage targeting seasonal and pandemic strains of the influenza virus. It currently has negative earnings.

More news for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) were recently published by: Prnewswire.com, which released: “First Participant Enrolled in BiondVax’s Universal Flu Vaccine Pivotal Phase 3 Clinical Trial” on August 08, 2018. Streetinsider.com‘s article titled: “Form 6-K BiondVax Pharmaceuticals For: Aug 10” and published on August 10, 2018 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.